Koichi Hara

Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD.

Part of Bayer AG, Monsanto Japan Ltd. is a Japanese company that manufactures a wide range of genetically altered seeds, fertilizers, and agrochemicals. The company is based in Tokyo, Japan.

JSR Micro, Inc. is a private company that specializes in materials innovation. It is based in Sunnyvale, CA. JSR Micro is ultimately controlled by the Government of Japan. The company was founded in 1990.

AGC Biologics, Inc. develops therapeutic proteins for early clinical trials. The firm offers integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. The company was founded in 2007 and is headquartered in Bothell, WA.

Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland.

Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States.

The Innovation Network Corporation of Japan (INCJ), a unique public-private partnership aimed at promoting innovation and enhancing the value of businesses in Japan, was launched in July 2009. Leveraging the rich history of Japanese technological prowess, the INCJ aims to provide financial, technological and management support in order to promote the creation of next-generation businesses through 'open innovation,' or the flow of technology and expertise beyond the boundaries of existing organizational structures. The INCJ will draw on funding as well as management and technological expertise from the public and private sectors. The INCJ is actively reviewing various investment opportunities in areas of environment and energy, electronics and IT, bio-tech, and infrastructure such as water supply, railway service, and nuclear power supply. Each investment will be thoroughly vetted to ensure it meets the exacting standards of the INCJ's Innovation Network Committee, which will make the final investment decisions. The INCJ is capitalized at 92 billion yen, with the Japanese government injecting 82 billion yen and 19 private corporations (refer to details in Appendix below) providing a further 10 billion yen. The government will also provide guarantees up to a total of 800 billion yen for INCJ investments, giving it an investment capability of approximately 900 billion yen (US$10 billion). The INCJ will be established for a period of 15 years.

Japan Medical Information Research Institute, Inc. engages in the collection, analysis, marketing, and consulting of medical information. The company was founded on July 14, 2005 and is headquartered in Tokyo, Japan.

NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA.

PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan.

Megakaryon Corp. operates as an pluripotent stem cells research laboratory. It produce platelets and red blood cells from iPS cell lines, and to develop blood products that do not depend on blood donations. The firm specializes in development of technologies to produce and store induced pluripotent stem cell derived human T cells. Megakaryon was founded by Genjiro Miwa on September 9, 2011 and is headquartered in Kyoto, Japan.

Quantum Biosystems, Inc. is a holding company that develops single-molecule DNA sequencers. It develops and commercializes sequencers based on quantum mechanics. The company was founded by Toshihiko Honkura and Masateru Taniguchi on January 7, 2013 and is headquartered in Osaka, Japan.

Atonarp, Inc. provides chemical analysis solutions and systems. The firm develops the Smart Spectrometer technology that focus on industrial gas process analytics applications in the energy, pharmaceutical, petrochemical and semiconductor industries. The company was founded by Tomoyoshi Sato and Prakash S. Murthy in November 2009 and is headquartered in Minato-Ku, Japan.

SCOHIA PHARMA, Inc. is a drug discovery venture that focuses on lifestyle-related diseases. The company is based in Fujisawa, Japan. The Japanese company has a strong development pipeline and an experienced R & D team that specializes in drug discovery, including compound creation, drug efficacy evaluation, and clinical development. The CEO of the company is Masanori Watanabe.

Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY.